Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear ...

Novartis' free cash flow increased by an impressive 5.7% in 2024, reaching $13.8 billion against $13.1 billion a year earlier. FCF even exceeded its net profit ($11.9 billion).

S wiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.. The hub, which is headquartered in Cambridge, Mass., and for years has been known as ...